Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18391329 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12442419 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL3205376 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12436525 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL3798438 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12441917 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| Water SCHEMBL30811226 | 0.99 | FAP (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL15189371 | 0.97 | FAP (0.41) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL29983999 | 0.96 | FAP (0.41) | FAPHTR2APDFSSTR3ALDH1A1 | |
| SCHEMBL23493270 | 0.96 | HTR2A (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240216522-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA | DYNE THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018087-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject | DYNE THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067744-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066140-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067743-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066139-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11911484-B2 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | DYNE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-9895450-B2 | Anti-wall teichoic antibodies and conjugates | GENENTECH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9884126-B2 | Anti-wall teichoic antibodies and conjugates | GENENTECH, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20180016325-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9822144-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9814784-B2 | Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same | CELLTRION, INC. (KR) | 2017-11-14 | — | — | US | disclosed |
| US-9803002-B2 | Anti-wall teichoic antibodies and conjugates | Genentench, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170073357-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-03-16 | — | — | US | disclosed |
| US-20150291613-A1 | FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018087-B2 | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject | MUSK, MYOF, TFRC | FAP 2319/4885HTR2A 3845/4885PDF 547/4885 |
| US-20170073357-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | FAP 4803/4885HTR2A 463/4885PDF 2530/4885 |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | FAP 2726/4885HTR2A 3491/4885PDF 3688/4885 |
| US-20240216522-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA | MUSK, ATXN2, ATXN10 | FAP 687/4885HTR2A 947/4885PDF 405/4885 |
| US-20240066140-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MUSK, MYOF, UTRN | FAP 1104/4885HTR2A 3954/4885PDF 614/4885 |
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, SMN1; SMN2 | FAP 327/4885HTR2A 3306/4885PDF 603/4885 |
| US-20240067744-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MYOF, MUSK, UTRN | FAP 2315/4885HTR2A 3404/4885PDF 408/4885 |
| US-20240066139-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | FAP 354/4885HTR2A 3212/4885PDF 548/4885 |
| US-20180016325-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885HTR2A 4166/4885PDF 581/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | FAP 1842/4885HTR2A 4428/4885PDF 1450/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | FAP 139/4885HTR2A 2906/4885PDF 638/4885 |
| US-20240067743-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MUSK, MYOF, UTRN | FAP 1104/4885HTR2A 3954/4885PDF 614/4885 |
| US-20150291613-A1 | FUNCTIONALIZED 9-BROMO-CAMPTOTHECIN DERIVATIVES | PCNA, TOP2A, TOP1 | FAP 2624/4885HTR2A 3372/4885PDF 841/4885 |
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | FAP 1360/4885HTR2A 2926/4885PDF 322/4885 |
| US-11911484-B2 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | MUSK, MYOF, MYLK2 | FAP 1360/4885HTR2A 2926/4885PDF 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.